当前位置: 首页 >> 检索结果
2395. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials.
作者: Jonathan I Silverberg.;Andreas Wollenberg.;Adam Reich.;Diamant Thaçi.;Franz J Legat.;Kim A Papp.;Linda Stein Gold.;Jean-David Bouaziz.;Andrew E Pink.;José Manuel Carrascosa.;Barbara Rewerska.;Jacek C Szepietowski.;Dorota Krasowska.;Blanka Havlíčková.;Monika Kalowska.;Nina Magnolo.;Sylvia Pauser.;Navid Nami.;Maxwell B Sauder.;Vipul Jain.;Kamila Padlewska.;Soo Yeon Cheong.;Patricia Fleuranceau Morel.;Liliana Ulianov.;Christophe Piketty.; .
来源: Lancet. 2024年404卷10451期445-460页
Nemolizumab, an interleukin (IL)-31 receptor subunit α antagonist, inhibits the IL-31 pathway of itch and skin inflammation in atopic dermatitis. Two international phase 3 studies were done to assess the efficacy and safety of nemolizumab in atopic dermatitis. In this Article we report results for the 16-week initial treatment period of both trials.
2396. Realigning the physical activity research agenda for population health, equity, and wellbeing.
作者: Ding Ding.;Sebastien Chastin.;Deborah Salvo.;Tracy Nau.;Klaus Gebel.;Miguel Adriano Sanchez-Lastra.;Mengyun Luo.;Inacio Crochemore-Silva.;Ulf Ekelund.;Adrian Bauman.
来源: Lancet. 2024年404卷10451期411-414页 2397. Many crises, one call to action: advancing gender equality in health in response to polycrises.
作者: Rajat Khosla.;Gita Sen.;Tedros Adhanom Ghebreyesus.;Winnie Byanyima.;Sima Bahous.;Debora Diniz.;Sara Hossain.;Natalia Kanem.;Ulrika Karlsson.;Laura Laski.;Dina Mired.;Catherine Russell.;Tlaleng Mofokeng.;Achim Steiner.;Volker Türk.;Johanna Riha.
来源: Lancet. 2024年404卷10454期731-733页 2400. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials.
作者: Robert Bissonnette.;Richard B Warren.;Andreas Pinter.;Tove Agner.;Melinda Gooderham.;Marie L A Schuttelaar.;Marie-Noëlle Crépy.;Luca Stingeni.;Esther Serra-Baldrich.;Keith Baranowski.;Sofie Korn.;Merle Kurvits.;Ursula Plohberger.;Natacha Strange Vest.;Sibylle Schliemann.; .
来源: Lancet. 2024年404卷10451期461-473页
Chronic hand eczema is a fluctuating, inflammatory, pruritic, often painful disease of hands and wrists that strongly impacts quality of life and occupational capabilities of patients. The aim of phase 3 DELTA 1 and DELTA 2 was to assess the efficacy and safety of twice-daily applications of the topical pan-Janus kinase inhibitor delgocitinib cream 20 mg/g versus cream vehicle in adults with moderate to severe chronic hand eczema.
|